Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND: Dapagliflozin in Non-Diabetic CKD
NCT03190694Phase 2Completed
- Start
- Nov 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in chronic kidney disease (CKD) and proteinuria. Started Nov 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)proteinuria
Beyond the preview
Go deeper on NCT03190694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190694.